How Patients Can Get NARCAN® Nasal Spray

Emergent BioSolutions, the maker of NARCAN® Nasal Spray, has partnered with all major wholesalers, distributors, and retail pharmacies to ensure broad availability of the product.

However, many patients may not know that an emergency treatment exists; therefore, it's important to continue to raise awareness through prescribing.

Emergent BioSolutions has also collaborated with major Pharmacy Benefits Managers and insurance companies (including Medicaid), to help make sure the cost of NARCAN® Nasal Spray to insured patients and caregivers is reasonable and affordable.

Is a Standardized Naloxone Program Right for Your Practice?

You may want to consider implementing a standardized naloxone program in your practice. If so, here are 3 steps to help you get started:

STEP 1:

Establish a Practice Protocol

  • Gather educational resources and counsel patients receiving opioids

STEP 2:

Appoint an Office Lead to Enforce the Program

  • Choose someone from your staff who will be most willing to help

STEP 3:

Establish Common Practice to offer NARCAN® Nasal Spray

  • Many patients receiving prescription opioids may be at risk; educate them and prescribe NARCAN® Nasal Spray, when appropriate

Visit HERE for additional resources.


INSURANCE

NARCAN® Nasal Spray has extensive public and private insurance coverage. In fact, 97% of U.S. insured lives have access to NARCAN® Nasal Spray.*

  • 49% of prescriptions for NARCAN® Nasal Spray have a co-pay of $0
  • 72% have a co-pay of $10 or less
  • 76% have a co-pay of $20 or less

*MMIT Formulary Analytics, February 2020. Coverage is subject to change without notice by a health plan or state.
IQVIA NPA Feb 2019 to Jan 2020. Specified co-pay on dispensed prescriptions. Includes Commercial, Medicare Part D, Fee-for-service and Managed Medicaid.

This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures.

Co-payment amounts are subject to change by plans without notice. Co-payment cost alone does not necessarily reflect a cost advantage in the outcome of the condition treated because there may be other variables that affect relative costs.

Patients may contact their health insurance provider to find out their coverage and co-pay requirements for NARCAN® Nasal Spray.

INDICATION AND USAGE

NARCAN® (naloxone HCl) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. Monitor for the development of opioid withdrawal.

In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes.

Abrupt Postoperative Reversal of Opioid Depression: Abrupt postoperative reversal of opioid depression may result in nausea, vomiting, sweating, tremulousness, tachycardia, hypotension, hypertension, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest. Serious sequelae of these events, including coma and death, have been reported. These events have primarily occurred in patients who had pre-existing cardiovascular (CV) disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone HCl.

Adverse Reactions: The following adverse reactions were observed in a NARCAN® Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.

NNS HCP ISI 08/2020

Please see full Prescribing Information.

References: 1. Opioid overdose. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/index.html. Accessed April 12, 2021. 2. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2020. 3. World Health Organization. Community management of opioid overdose. 2014:1-88. 4. U.S. Surgeon General's advisory on naloxone and opioid overdose. U.S. Department of Health and Human Services website. https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html. Accessed April 12, 2021. 5. NARCAN® Nasal Spray [prescribing information]. Plymouth Meeting, PA: Emergent BioSolutions Inc.; 2020. 6. Mell HK, Mumma SN, Hiestand B. Emergency medical services response times in rural, suburban, and urban areas. JAMA Surg. 2017;152(10):983-984. 7. Opioid overdose. World Health Organization website. http://www.who.int/substance_abuse/information-sheet/en. Updated August 28, 2020. Accessed April 12, 2021. 8. Calculating total daily dose of opioids for safer dosage. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose­a.pdf. Accessed April 12, 2021. 9. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Chronic Pain — United States, 2016. Morb Mortal Wkly Rep. 2016;65(1):1-49. 10. National Safety Council. Prescription opioid pain killer public opinion poll. October 2017. 11. San Francisco Department of Public Health. Naloxone for opioid safety: a provider's guide to prescribing naloxone to patients who use opioids. January 2015. https://prescribetoprevent.org/wp2015/wp-content/uploads/CA.Detailing_Provider_final.pdf. Accessed April 12, 2021.

INDICATION AND USAGE

NARCAN® (naloxone HCl) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. Monitor for the development of opioid withdrawal.

In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes.

Abrupt Postoperative Reversal of Opioid Depression: Abrupt postoperative reversal of opioid depression may result in nausea, vomiting, sweating, tremulousness, tachycardia, hypotension, hypertension, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest. Serious sequelae of these events, including coma and death, have been reported. These events have primarily occurred in patients who had pre-existing cardiovascular (CV) disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone HCl.

Adverse Reactions: The following adverse reactions were observed in a NARCAN® Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.

NNS HCP ISI 08/2020

Please see full Prescribing Information.

References: 1. Opioid overdose. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/index.html. Accessed April 12, 2021. 2. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2020. 3. World Health Organization. Community management of opioid overdose. 2014:1-88. 4. U.S. Surgeon General's advisory on naloxone and opioid overdose. U.S. Department of Health and Human Services website. https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html. Accessed April 12, 2021. 5. NARCAN® Nasal Spray [prescribing information]. Plymouth Meeting, PA: Emergent BioSolutions Inc.; 2020. 6. Mell HK, Mumma SN, Hiestand B. Emergency medical services response times in rural, suburban, and urban areas. JAMA Surg. 2017;152(10):983-984. 7. Opioid overdose. World Health Organization website. http://www.who.int/substance_abuse/information-sheet/en. Updated August 28, 2020. Accessed April 12, 2021. 8. Calculating total daily dose of opioids for safer dosage. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose­a.pdf. Accessed April 12, 2021. 9. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Chronic Pain — United States, 2016. Morb Mortal Wkly Rep. 2016;65(1):1-49. 10. National Safety Council. Prescription opioid pain killer public opinion poll. October 2017. 11. San Francisco Department of Public Health. Naloxone for opioid safety: a provider's guide to prescribing naloxone to patients who use opioids. January 2015. https://prescribetoprevent.org/wp2015/wp-content/uploads/CA.Detailing_Provider_final.pdf. Accessed April 12, 2021.